Article information
Full text is only aviable in PDF
References
[1.]
L.W. Moreland, M.E. Weinblatt, E.C. Keystone, J.M. Kremer, R.W. Martin, M.H. Schiff, et al.
Tratamiento con etanercept en adultos con artritis reumatoide establecida: 7 años de experiencia clínica.
J Rheumatol, 33 (2006), pp. 854-861
[2.]
J.L. Marenco de la Fuente.
Aplicaciones de anticuerpos monoclonales y productos de biotecnología en el tratamiento de las enfermedades inflamatorias crónicas.
Rev Clin Esp, 205 (2005), pp. 127-136
[3.]
A.I. Sánchez Atrio, A. Pérez Gómez, E. Cuende Quintana, C. Bohórquez Heras, M. Álvarez-Mon Soto.
Actualizaciones. Artritis reumatoide (II).
Medicine, 10 (2009), pp. 1927-1932
[4.]
N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliveiro, G. Sandberg, H. Crayton, et al.
Demyelination ocurring during anti-tumor necrosis factor α therapy for inflammatory arthritides.
Arthritis Rheum, 44 (2001), pp. 2862-2869
[5.]
A. Fromont, J. De Seze, M.C. Fleury, J.F. Maillefert, T. Moreau.
Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
Cytokine, 45 (2009), pp. 55-57
[6.]
N.L. Sicotte, R.R. Voskuhl.
Onset of multiple sclerosis associated with anti-TNF therapy.
Neurology, 57 (2001), pp. 1885-1888
[7.]
M.A. Hamon, G. Nicolas, F. Deviere, F. Letournel, F. Dubas.
Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature.
Rev Neurol (Paris), 163 (2007), pp. 1232-1235
[8.]
P. Lozeron, C. Denier, C. Lacroix, D. Adams.
Long-term course of demyelinating neuropathies ocurring during tumor necrosis factor-α-blocker therapy.
Arch Neurol, 66 (2009), pp. 490-497
Copyright © 2010. Sociedad Española de Neurología
